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Abstract: Despite recent advances in diagnosis and treatment, the prognosis of primary 
intraocular lymphoma (PIOL) remains poor, and the optimal treatment has yet to be deﬁ  ned. 
This review presents an overview of the current status of PIOL with a focus on recent advances 
in diagnosis and treatment. Recent studies show a decreasing time interval from symptom pre-
sentation to diagnosis, likely due to increased awareness of the disease and improved diagnostic 
tools. Advances in the pathologic characterization of PIOL have been made over the past years, 
and the development of PIOL animal models can offer the opportunity to study aspects of PIOL 
pathology, pathogenesis and treatment. Regarding treatment of PIOL, recent larger case series 
favor the use of systemic chemotherapy plus local ocular treatment as ﬁ  rst-line management 
for patients with concomitant PIOL and PCNSL. For patients with isolated PIOL, the current 
trend focuses on local ﬁ  rst-line treatment and early diagnosis of PIOL. Future studies are needed 
to conﬁ  rm these trends. Future directions in the management of PIOL should include studies 
about pathogenesis, prognostic factors, and treatment optimization. In the future, monoclonal 
antibodies and radioimmunotherapy could prove useful for PIOL treatment.
Keywords: chemotherapy, diffuse large B-cell lymphoma, non-Hodgkin’s lymphoma, primary 
central nervous system lymphoma, primary intraocular lymphoma, radiotherapy
Introduction
Primary intraocular lymphoma (PIOL) is a malignant non-Hodgkin’s lymphoma (NHL) 
which either occurs independently to, or in association with primary central nervous system 
lymphoma (PCNSL). It involves the retina, the vitreous chamber and/or the optic nerve 
and has to be distinguished from secondary intraocular lymphoma (IOL), an ocular mani-
festation of systemic NHL, which predominantly inﬁ  ltrates the uveal tract, particularly the 
choroid (Whitcup et al 1993; Coupland et al 2004). The incidence of PCNSL is 0.3% per 
100,000 person years in immunocompetent individuals and 4 to 5 per 1000 person years in 
patients with AIDS (Cote et al 1996; Behin et al 2003). PIOL has become more frequent 
due to a threefold increase in the incidence of PCNSL from 1973 to 1984 (Eby et al 1988), 
but the incidence of PCNSL has stabilized recently (Kadan-Lottick et al 2002). Ocular 
involvement develops in about 15 to 25% of patients with PCNSL (Hochberg and Miller 
1988; Levy-Clarke et al 2005) and is bilateral in 80% of cases (Freeman et al 1987). Sixty 
to 80% of patients with initial PIOL eventually develop central nervous system (CNS) 
disease with a mean of 29 months (Freeman et al 1987; Whitcup et al 1993; Akpek, Ahmed 
et al 1999). Most PIOL are diffuse large B-cell lymphomas (DLBCL), according to the 
updated World Health Organization (WHO) lymphoma classiﬁ  cation (Jaffe et al 2001); 
secondary IOL usually corresponds to the subtype of systemic lymphoma (Coupland 
et al 2004). Intraocular T-cell lymphomas are rare, and most cases occur secondary to 
primary cutaneous or other systemic T-cell lymphomas, whereas only few T-IOL cases 
without systemic involvement have been described (Char, Ljung, Deschenes et al 1988; 
Coupland et al 1999; Coupland, Anastassiou et al 2005).Clinical Ophthalmology 2007:1(3) 248
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The prognosis of PIOL, particularly when concomitant 
cerebral involvement is present, is poor with a two-year 
overall survival (OS) of 39% (Ferreri et al 2002) and a 
median OS of 33 months (with brain involvement) and 
57 months (isolated PIOL), respectively (Grimm, Pulido, 
Jahnke et al 2006; Grimm, Pulido, Omuro et al 2006). The 
optimal treatment of PIOL is controversial and has yet to be 
deﬁ  ned, mainly due to treatment data being limited to small 
studies and case reports. The aim of this review is to present 
an overview of current diagnosis and management of PIOL, 
focusing on recent advances in diagnosis and treatment.
Pathogenesis
The pathogenesis of PIOL/PCNSL remains unknown. In 
immunosuppressed patients, PCNSL is almost invariably 
associated with a latent infection of the B-cells by the 
Epstein-Barr virus (Chan et al 1999, 2002; Tuaillon and 
Chan 2001). Furthermore, PCNSL occurs much more fre-
quently among AIDS patients than in immunocompetent 
individuals (Cote et al 1996). In immunocompetent persons, 
human herpesvirus-8 and Toxoplasma gondii have been 
implicated in the pathogenesis of PCNSL (Chan et al 1999, 
2002; Tuaillon and Chan 2001). Chemokines, substances 
involved in the chemotaxis of leukocytes during inﬂ  amma-
tory processes, could play a role in PIOL pathogenesis. The 
chemokine receptors CXCR4 and CXCR5 are expressed on 
B-cells, whereas their chemokine ligands, CXCL12 (SDF-1) 
and CXCL13 (BLC), were detected in the retinal pigment 
epithelium, suggesting a role of receptor-ligand interactions 
in the homing of PIOL cells to the retinal pigment epithelium 
(Chan et al 2003). There also is evidence that chemokines 
and their receptors may be involved in PCNSL pathogenesis 
(Smith et al 2003; Jahnke, Coupland et al 2005).
Clinical presentation and diagnosis
General considerations
PIOL usually presents in the ﬁ  fth and sixth decade as a 
nonspeciﬁ  c, chronic and relapsing uveitis and vitritis resistant 
to corticosteroids. There appears to be a slight male predomi-
nance for this disease (Schabet 1999). Because of its gradual 
onset and ability to imitate other ocular syndromes, delays 
are common before the diagnosis of PIOL is established 
(Barr et al 1975; Char, Ljung, Miller et al 1988; Whitcup 
et al 1993; Cassoux et al 2000; Rothova et al 2001; Coupland 
et al 2003; Davis et al 2004; Zaldivar et al 2004). A median 
interval of 21–24 months from the onset of ocular symptoms 
to deﬁ  nitive diagnosis has been reported in the older literature 
(Barr et al 1975; Char, Ljung, Miller et al 1988; Peterson 
et al 1993; Whitcup et al 1993). More recent data, however, 
suggest that the diagnosis can be achieved within 12 months 
in 80% of patients (Akpek, Ahmed et al 1999) or within a 
median of 6 months (Jahnke, Korfel et al 2006). The delays 
in diagnosis establishment have become shorter due to a 
number of reasons. These include: (1) an increased awareness 
by clinicians and pathologists of the disease; and (2) the 
increased use of improved diagnostic tools, such as cho-
rioretinal biopsy, immunocytology/-histology, biochemical 
analysis and polymerase chain reaction (PCR). The cytolytic 
effect of corticosteroids on lymphoma cells can negatively 
impact the diagnostic yield; thus, the administration of cor-
ticosteroids should be avoided before specimen sampling 
(Whitcup et al 1993).
History and ophthalmic examination
PIOL most commonly presents as a chronic uveitis and 
vitritis, initially responsive but later refractory to cortico-
steroids. Because of its insidious onset, relapsing-remitting 
nature and ability to mimic several other conditions 
resulting in uveitis syndromes (eg, tuberculosis, sarcoidosis, 
toxoplasmosis, acute retinal necrosis, multifocal choroiditis) 
(Chan and Wallace 2004), the clinical presentation of PIOL 
is commonly referred to as masquerade syndrome (Char, 
Ljung, Miller et al 1988; Whitcup et al 1993; Cassoux et al 
2000; Rothova et al 2001; Coupland et al 2003, 2004; Davis 
2004; Zaldivar et al 2004). Patients mainly complain of blurred 
vision, ﬂ  oaters and painless vision loss. Less frequent symp-
toms consist of red eye, ocular pain and photophobia (Freeman 
et al 1987; Char, Ljung, Miller et al 1988; Peterson et al 1993; 
Whitcup et al 1993; Akpek, Ahmed et al 1999; Cassoux et al 
2000; Buggage et al 2001; Chan et al 2002; Chan and Wallace 
2004; Coupland et al 2004; Davis 2004; Zaldivar et al 2004; 
Levy-Clarke et al 2005; Jahnke, Korfel et al 2006).
Vitritis is the most common ﬁ  nding upon ocular exami-
nation. Fundus examination typically reveals characteristic 
retinal or subretinal yellow inﬁ  ltrates (Chan and Wallace 
2004; Levy-Clarke et al 2005). Subretinal ﬁ  brosis and atro-
phy of the retinal pigment epithelium may be evident if these 
lesions resolve (Dean et al 1996).
Fluorescein angiography and ultrasound can be helpful 
adjuncts in the diagnosis of PIOL. Fluorescein angiography 
frequently reveals window defects (indicating tumor inﬁ  l-
trates), hypoﬂ  uorescent lesions, vasculitis, granulations, 
late staining and blockage at the level of the retinal pigment 
epithelium, whereas signs of inﬂ  ammation like perivascular 
leakage and macular edema are typically lacking (Cassoux 
et al 2000; Velez et al 2002). Ultrasound may reveal debris Clinical Ophthalmology 2007:1(3) 249
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in the vitreous, choroidal and scleral thickening, widening 
of the optic nerve, elevated lesions in the choroid and retinal 
detachment (Ursea et al 1997).
Pathologic diagnosis
Vitreous sampling and cytologic diagnosis
Cytologic examinations of vitreous samples are generally 
the ﬁ  rst step in the pathologic diagnosis of PIOL. Vitreous 
specimens can be obtained by pars plana (three-port) vitrec-
tomy or vitreal or ﬁ  ne needle aspiration (Davis et al 1992; 
Whitcup et al 1993; Lobo and Lightman 2003; Coupland et al 
2004). Anterior chamber aspiration cytology enhanced by the 
cytospin technique may provide a less invasive alternative 
to vitrectomy (Finger et al 2006). The vitreous frequently 
contains neoplastic cells which form sheets, and cells in the an-
terior chamber are present in 50%–75% of patients (Peterson 
et al 1993; Whitcup et al 1993; Bardenstein 1998; Velez et al 
2000; Hoffman et al 2003; Coupland et al 2004; Chan and 
Wallace 2004; Jahnke, Korfel et al 2006). Rapid processing 
is crucial due to the usually small number of neoplastic cells 
in the specimen that may be undergoing necrosis.
Chorioretinal biopsy, ﬁ  ne-needle aspiration biopsy 
and enucleation
If vitrectomy specimens have been insufﬁ  cient to establish a 
ﬁ  nal diagnosis, a chorioretinal biopsy or ﬁ  ne-needle aspira-
tion biopsy should be considered. These techniques are more 
likely to yield a sufﬁ  cient concentration of neoplastic cells 
(Kirmani et al 1987; Levy-Clarke et al 2001; Tuaillon and 
Chan 2001; Bechrakis et al 2002; Coupland et al 2003). If 
all the above-mentioned diagnostic procedures have failed, 
enucleation of a blind eye may be considered, especially if 
the eye is painful due to secondary glaucoma.
Immunophenotyping
Flow cytometry and immunohistochemistry are able to 
identify lymphoma cells and demonstrate their monoclonality 
by B-cell and plasma cell markers (CD19/20/22, BCL-6, 
MUM1) and kappa or lambda light chain restriction. How-
ever, the accuracy of ﬂ  ow cytometry is variable among 
different centers. Some studies found ﬂ  ow cytometry more 
accurate than conventional cytology in the diagnosis of PIOL, 
whereas other studies reported the opposite ﬁ  nding (Char, 
Ljung, Deschenes et al 1988; Davis et al 1997; Rothova 
et al 2001).
A study comparing 50 cases of PIOL/PCNSL with 50 sys-
temic DLBCL specimens regarding the expression of a vari-
ety of B-cell associated immunoglobulin transcription factors 
using immunohistochemistry found notable differences 
between both groups. For example, immunoglobulin expres-
sion could be demonstrated in 92% of PIOL/PCNSL but 
in only 54% of systemic DLBCL, thus providing evidence 
that PIOL/PCNSL and systemic DLBCL represent distinct 
entities with PIOL/PCNSL derived from mature B-cells that 
have undergone the germinal center reaction (Coupland, 
Loddenkemper et al 2005).
Interleukins
The cytokines interleukin (IL)-6 and IL-10 have been impli-
cated in the discrimination of PIOL and ocular inﬂ  ammatory 
processes. Neoplastic B-lymphocytes preferentially secrete 
IL-10, whereas IL-6 is associated with inﬂ  ammation (Chan 
et al 1995; Choi et al 2006). Vitreal levels of these cytokines 
can be detected by enzyme-linked immunosorbent assay. An 
association of PIOL with an increased ( 1) IL-10 to IL-6 
ratio has been reported (Chan et al 1995; Whitcup et al 1997; 
Cassoux et al 2001; Wolf et al 2003). However, another report 
found an elevated ratio in only 8/14 patients and a ratio of  1 
in one patient with PIOL (Akpek, Maca et al 1999).
Molecular studies
Over the recent years, PCR has emerged as a useful adjunct 
in the diagnosis of PIOL, and can increase diagnostic sen-
sitivity and speciﬁ  city compared to other diagnostic tools. 
PCR and microdissection for gene rearrangements of the 
immunoglobulin heavy (IgH) chain gene has proven useful 
for demonstrating monoclonality of a B-cell population in 
PIOL and PCNSL (Shen et al 1998; Coupland et al 2003; 
Jahnke, Hummel et al 2006). In a recent study, the sensitivity 
value of immunoglobulin IgH rearrangement analysis (0.64) 
was superior to that of vitreous ﬂ  uid cytopathology (0.24) 
and ﬂ  ow cytometry (0.36), whereas the speciﬁ  city value was 
1.0 with all three methods (Baehring et al 2005). PCR of the 
third hypervariable or complementary determining region 
(CDR3) of the IgH variable region is frequently used (Chan 
2003; Gorochov et al 2003). New primers have recently been 
developed by a European concerted action to increase the 
chances of detecting monoclonality in lymphoproliferations 
(van Dongen et al 2003). PCR and microdissection have also 
been used for the detection of the t(14; 18) translocation (ie, 
translocation between the genes for BCL-2 and IgH) (Shen 
et al 1998; Wallace at al 2006). There is evidence that PIOL 
has unique patterns of BCL-2, BCL-6 and BCL-10 expression 
as compared to systemic DLBCL and PCNSL, with PIOL 
resembling germinal center B-cell DLBCL (Wallace et al 
2006). The notion that PIOL is derived from mature B-cells Clinical Ophthalmology 2007:1(3) 250
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that have undergone the germinal center reaction could be 
further underscored in a recent study with 16 PIOL cases 
analyzing somatic hypermutations in clonally rearranged 
IgH chain variable regions (Coupland, Hummel, Muller et al 
2005). It has been widely hypothesized that cerebral and 
ocular lymphoma manifestations in PCNSL patients with 
ocular involvement are derived from the same neoplastic 
clone, and this could recently be shown by IgH PCR analysis 
in one patient (Coupland, Hummel, Stein et al 2005). The 
close relationship between PIOL and PCNSL could be sub-
stantiated in a recent study, demonstrating the presence of 
the same variable region of the clonally rearranged IgH chain 
gene in three out of six cases of oculocerebral lymphoma 
(Coupland, Hummel, Muller et al 2005).
Diagnosis and response evaluation in 
PIOL and PCNSL: International workshop 
recommendations
Baseline evaluation
Since PIOL is closely related to PCNSL and vice versa, every 
PIOL and PCNSL patient must be thoroughly evaluated for 
both the presence of cerebral and ocular disease. In an effort 
to standardize baseline evaluation, response criteria and man-
agement of PIOL and PCNSL, the International PCNSL Col-
laborative Group (IPCG) has recently published guidelines 
and recommendations for the diagnosis and management of 
PIOL and PCNSL (Abrey et al 2005).
Baseline clinical and laboratory evaluation should include 
a comprehensive physical and neurological examination and 
the recording of parameters that have been implicated as 
prognostic factors in PCNSL, eg, age, performance status, 
and serum lactate dehydrogenase (Ferreri, Blay et al 2003). 
Peripheral lymph nodes should be examined in all patients 
and the testes in elderly men to search for systemic disease. 
All patients should be tested for HIV infection. Evaluation of 
neurocognitive function is important to monitor treatment suc-
cess and possible treatment-related neurocognitive decline.
A gadolinium-enhanced magnetic resonance imaging 
(MRI) scan is the imaging method of choice for PCNSL. 
Computed tomography (CT) should be used only if MRI 
is contraindicated or unavailable. The role of MRI and CT 
for visualizing ocular involvement is limited since they lack 
sensitivity and speciﬁ  city. In seven patients with biopsy-
proven PIOL, only four had ocular ﬁ  ndings on imaging, 
and these were not speciﬁ  c for PIOL (Kuker et al 2002). For 
the exclusion or conﬁ  rmation of ocular disease, a slit-lamp 
examination should be performed.
Patients should undergo cytologic cerebrospinal ﬂ  uid 
(CSF) evaluation for the presence of leptomeningeal involve-
ment, and total protein should be recorded in all patients 
since it has been reported as a prognostic factor in PCNSL 
(Ferreri, Blay et al 2003).
Occult systemic disease has been reported in up to 17% of 
patients initially thought to have isolated CNS involvement 
(Nelson et al 1992; O’Neill et al 1995; Ferreri et al 1996; 
Jahnke, Hummel et al 2006). Thus, a complete systemic 
staging is warranted in every patient, including CT scans 
of the chest, abdomen and pelvis and bone marrow aspirate 
and biopsy.
All PIOL and PCNSL patients should have histo-
pathologic or cytologic conﬁ  rmation of the diagnosis. The 
preferred diagnostic procedures are stereotactic biopsy for 
parenchymal mass lesions, CSF analysis in patients with 
leptomeningeal involvement and vitrectomy in cases sus-
pected of PIOL. Since histologic diagnosis and response 
assessment can be affected by the administration of glu-
cocorticosteroids, their administration should be avoided 
whenever possible.
Response assessment and criteria
Gadolinium-enhanced MRI is the gold standard for the 
response assessment of parenchymal lesions. Detailed 
ophthalmologic examinations and CSF analysis are recom-
mended only if these studies were positive at baseline or if 
clinically indicated by new signs and symptoms.The response 
criteria for parenchymal and CSF disease have been reported 
in detail in the manuscript summarizing the aforementioned 
IPCG Workshop (Abrey et al 2005). The response criteria 
for PIOL are summarized in Table 1.
Treatment and prognosis
An overview of clinical studies on the treatment of PIOL is 
provided in Tables 2 and 3.
General considerations about the 
treatment of PCNSL and PIOL
The treatment of PCNSL is signiﬁ  cantly different from that 
of systemic NHL. Therapies effective for extra-CNS NHL 
have not been successful in PCNSL due to the inability 
of most chemotherapeutic agents to sufﬁ  ciently cross the 
blood-brain barrier (Schultz et al 1996; O’Neill et al 1999; 
Mead et al 2000). As opposed to other brain tumors, there 
is no role for resection in the treatment of PCNSL; its use is 
limited to diagnostic purposes (Hunt et al 2006). Until the 
early 1990s, WBRT was considered the standard treatment Clinical Ophthalmology 2007:1(3) 251
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of PCNSL. However, disease relapse almost invariably 
occurs, resulting in a median OS of only 12 months (Nelson 
et al 1992). Today, it is generally believed that high-dose 
methotrexate-based chemotherapy should be part of the 
ﬁ  rst-line treatment for the vast majority of patients. With 
high-dose methotrexate alone, a response rate of 38 to 74% 
and a median OS of 22.8+ to 25 months have been reported 
(Herrlinger et al 2002; Batchelor T et al 2003; Herrlinger 
et al 2005). Methotrexate-based intensive multi-agent che-
motherapy has led to a response rate of 71%, a median OS 
of 50 months, and a ﬁ  ve-year OS of 43% (Pels et al 2003). 
Combined modality therapy with high-dose methotrexate-
based chemotherapy followed by WBRT yields ﬁ  ve-year 
OS rates up to 32% (DeAngelis et al 2002), but is associ-
ated with rates of neurotoxicity as high as 100% in patients 
over 60 years (Abrey et al 1998). Thus, postponing WBRT 
until progression or relapse has been suggested. Compared 
to combined modality therapy, intraarterial chemotherapy 
in conjunction with blood-brain barrier disruption seems 
able to yield equal response and survival rates while pre-
serving neurocognitive function in PCNSL (McAllister 
et al 2000). The role of intrathecal therapy and high-dose 
chemotherapy followed by autologous stem cell support in 
PCNSL remains to be deﬁ  ned (Soussain et al 2001; Khan 
et al 2002; Abrey et al 2003; Ferreri, Abrey et al 2003; 
Illerhaus et al 2006).
The efﬁ  cacy of systemic chemotherapy in PIOL depends 
on intraocular pharmacokinetics which are not yet fully 
understood. The blood-retinal barrier and the blood-aqueous 
barrier represent hindrances for diffusion of drugs from the 
blood into ocular tissues. The retinal vessels and the retinal 
pigment epithelium are the two sites of the blood-retinal 
barrier which represents the counterpart of the BBB in the 
eye (Raviola 1977; Cunha-Vaz 1979). The blood-aqueous 
barrier is a barrier between the blood and ocular tissues 
and ﬂ  uids posterior to the iris plane (Freddo 2001). Drug 
penetration through these barriers depends on several drug 
characteristics, with lipid solubility playing the major role. 
The major advantage of systemic chemotherapy in PIOL is 
the simultaneous treatment of cerebral involvement which 
should be suspected in all patients with PCNSL, at least at 
a microscopic level.
Ocular radiotherapy
Local radiotherapy had been widely used in PIOL, as lym-
phoma cells are highly sensitive to radiation (Margolis et al 
1980). Almost all patients, however, die of cerebral relapse 
after a median survival of 12–20 months (Fine and Mayer 
1993; Ferreri et al 2002). Additionally, severe side effects of 
radiotherapy, eg, optic neuropathy, retinopathy, glaucoma, 
dry eye syndrome, corneal defects, and cataracts, led to 
permanent visual loss in some long-term survivors (Char, 
Ljung, Miller et al 1988; Buggage et al 2001). Furthermore, 
ocular radiation has no effect on the prevention of PCNSL 
and can only be administered once.
Intravitreal chemotherapy
Intravitreal drug instillation bypasses the ocular barriers, 
which signiﬁ  cantly improves the intraocular delivery of 
hydrophilic drugs like methotrexate. Moreover, the toxicity 
seen with systemic treatment can be avoided. Therapeutic 
methotrexate doses are maintained over ﬁ  ve days after 
intravitreal administration (de Smet et al 1999). In a study 
of four PIOL patients treated with intravitreal methotrex-
ate, complete remission was achieved in all patients, and 
no relapses were observed with follow-up ranging from 9 
to 19 months (Fishburne et al 1997). Similar results could 
be obtained in a larger study with 16 patients (Smith et al 
2002). Combination therapy with intravitreal methotrexate 
and thiotepa yielded a sustained remission in one patient with 
relapsed PIOL (de Smet et al 1999). However, intravitreal 
therapy does not prevent disease in the CNS or the contra-
lateral eye. Furthermore, complications such as cataracts, 
corneal epitheliopathy, maculopathy, vitreous hemorrhage 
and optic nerve atrophy, are frequently observed with intra-
vitreal methotrexate administration (Smith et al 2002).
Systemic chemotherapy
Methotrexate, cytarabine, ifosfamide and trofosfamide are 
able to penetrate the blood-ocular barriers in cytostatic con-
centrations and therefore have been successfully used for 
the treatment of PIOL in intravenous or oral formulations 
(Baumann et al 1986; Strauchen et al 1989; de Smet et al 
1996; Henson et al 1999; Batchelor T et al 2003; Batchelor 
TT et al 2003; Jahnke et al 2004; Jahnke, Wagner et al 2005). 
Table 1 Response criteria for PIOL as published by the IPCG 
(adapted from Abrey et al 2005)
Response  Corticosteroid  Ocular examination
 dose
Complete remission  None  Normal
Unconﬁ  rmed    Any  Minor retinal pigment epithelium 
complete remission    abnormality
Partial remission  Irrelevant  Decrease in retinal inﬁ  ltrate or
   vitreous  cells
Progressive disease  Irrelevant  Recurrent or new ocular diseaseClinical Ophthalmology 2007:1(3) 252
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Table 2 Summary of clinical studies over the past 20 years (in chronological order) using chemotherapy or immunotherapy alone as 
treatment for PIOL
Author(s) and   Treatment   Chemotherapeutic   No. of   Ocular   Ocular   Survival
year of   modalitya agentsa PIOL    response  relapses 
publication     patients     
Strauchen 1989  High-dose IV   Cytarabine  6  5/6 (1 CR, 4   1/5  Not reported on an 
 chemo      PR)    individual  basis
Soussain 1996  High-dose IV   Thiotepa, busulfan,   5  5/5 (5 CR)  2/5   3 alive in CR at 26+ 
 chemo  +   cyclophosphamide        months, 2 alive after 
  autologous bone           ocular relapse at 27+, 
 marrow            16+  months
 transplantation         
Fishburne 1997  High-dose IA   MTX (as IO   4  4/4 (4 CR)  0/4  Not reported on an 
 chemo  + BBBD, IO   treatment)        individual basis
 chemo         
Sandor 1998  High-dose IV   Thiotepa, vincristine,   5  5/5 (3 CR, 2   0/5   3 alive in CR, 2 died of 
  chemo, IT chemo  MTX,     PR)    cerebral or spinal disease
   dexamethasone,         
   cytarabine       
De Smet 1999  IO chemo  MTX, thiotepa  1  1/1 (1 CR)  0/1   1 alive in CR at 30+ 
           months
Soussain 2001  High-dose IV   Thiotepa, busulfan,   11  10/11 (9 CR, 1   2/10   7 alive in CR, 1 alive with 
 chemo  +   cyclophosphamide    PR)    ocular PD, 2 died due to 
  hematopoietic stem          tumor progression, 1 died
  cell rescue           due to unknown causes; 
            median follow-up 41 
            months for all study 
           patients
Smith 2002  High-dose IV/IA   MTX (as IO   16  16/16 (16 CR)  3/16   6 deaths, all due to 
 chemo  ± BBBD,   treatment)        intracranial progression
  IT chemo, PO          
  chemo, IO chemo         
Abrey 2003  High-dose IV   MTX, cytarabine,   2  2/2  1/2   1 in CR at 36.8+ months, 
 chemo  +   carmustine,         1 alive with intracranial 
  hematopoietic stem  etoposide, melphalan        disease at 37.4+ months
 cell  rescue         
Batchelor,   High-dose IV   MTX  9  7/9 (6 CR, 1   3/7   4 alive in CR at 8+, 15+, 
Kolak 2003  chemo      PR)    20+, 36+ months; 2 died 
            of intracranial disease
Batchelor,   High-dose IV   MTX  5  4/5 (4 CR)  Not reported    Not reported on an 
Carson 2003  chemo        on an individual   individual basis
         basis 
Mason 2003  IT chemo  MTX, cytarabine  2  2/2  0/2   2 alive in CR at 5+ years
Jahnke 2004  PO chemo  Trofosfamide  2  2/2 (2 CR)  1/2   1 alive in CR at 8+ 
            months, 1 alive with 
            ocular relapse at 18+ 
           months
Rubenstein 2004  IT immunotherapy  Rituximab  1  1/1  Not reported    Not reported on an 
          on an individual   individual basis
         basis 
Jahnke 2005  High-dose IV   Ifosfamide,   8  8/8 (6 CR, 2   2/8   5 alive in CR, 2 alive in
  chemo, PO chemo  trofosfamide    PR)    PR, 1 died due to 
           suspected  intracranial 
           progression;  overall 
           survival  6+ to 35+ months
aPatients may or may not have received all listed modalities and agents; see referenced articles for details.
Abbreviations: PIOL, primary intraocular lymphoma; IV, intravenous; CR, complete remission; PR, partial remission; IA, intraarterial; BBBD, blood-brain barrier disruption; 
IO, intraocular; MTX, methotrexate; IT, intrathecal; PO, oral.Clinical Ophthalmology 2007:1(3) 253
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Systemic therapy has the potential beneﬁ  t of being able to 
treat concurrent CNS disease in PIOL.
Most studies on systemic chemotherapy for PIOL are 
high-dose methotrexate-based. In one study, nine patients 
with concurrent PCNSL and PIOL or isolated IOL were 
treated with intravenous methotrexate at a dose of 8 g/m2. 
Micromolar concentrations of methotrexate were present in 
the vitreous in eight of eight patients, and were lower in the 
Table 3 Summary of clinical studies over the past 20 years (in chronological order) using chemotherapy/immunotherapy and radio-
therapy as treatment for PIOL
Author(s)   Treatment  Chemotherapeutic  No. of  Ocular  Ocular  Survival
and year of  modalitya agentsa PIOL  response  relapses 
publication     patients
Valluri  High-dose  MTX, cytarabine  3  3/3 (3 CR)  0/3   3 alive in CR 31+, 30+, 
1995  IV chemo, IT           30+ months after
  chemo, WBRT,          completion of therapy
 ORT
Cassoux  Retrospective  Retrospective  44  Not reported   Not reported   12 alive in CR and 14 
2000  series with  series with    on an  on an  have died after an average
  various  various regimens    individual basis  individual basis   follow-up of 33.1 months
 modalities
Ferreri  High-dose  Vincristine, MTX,  2  2/2 (2 CR)  1/2   1 alive in CR at 44+
2001  IV chemo, PO  procarbazine        months; 1 died due to
  chemo, WBRT          neurotoxicity after 24 months
Ferreri  High-dose  MTX, cytarabine,  22  15/22 (13  9/15   2-year failure-free 
2002  IV chemo, IT  CHOP    CR, 2 PR)    survival 34%, 2-year 
  chemo, WBRT,          overall survival 39%
 ORT
Hoffman  Retrospective  Retrospective  10  Not reported  2   1 alive in CR at 103+
2003  series with  series with    on an individual    months, 1 alive with disease
  various  various regimens    basis    at 24+ months, 8 have
  modalities          died; median overall
            survival 16 monthsb
Hormigo  (High-dose)  MTX, cytarabine,  31  29/31 (24   8/29   Median survival 60 months
2004  IV chemo, IT  vincristine, procarbazine,    CR, 5 PR)    for isolated PIOL vs
  chemo, PO  thiotepa,         35 months for PIOL +
  chemo, WBRT,  CHOP, rituximab        intracranial disease (p   0.05)
 ORT
Berenbom  (High-dose)  MTX, vincristine,  12  Not reported  2/12  1 alive in CR, 4 alive
2006  IV chemo, PO  rituximab, procarbazine,    on an individual    with cerebral disease,
  chemo, WBRT,  cytarabine, carboplatin,    basis    7 died of cerebral disease
 ORT  dexamethasone
Grimm, Pulido,  Retrospective  Retrospective  225  Not reported  Not reported  Median progression-free
Omuru 2006  series with  series with    on an individual  on an individual  survival 18.7 months,
  various  various regimens    basis  basis   median overall
  modalities          survival 33.1 months
Grimm, Pulido,  Retrospective  Retrospective  81  Not reported  47 total relapses:  Median progression-free
Janke 2006  series with  series with    on an individual  30% ocular, 15%  survival 29.6 months,
 various  various  regimens    basis  ocular  + cerebral  median overall
  modalities          survival 57 months
Isobe  Chemo, WBRT,  Retrospective   15  13/15 CR or  1/13  Median overall survival
2006  ORT  series with    CRu    41 months, 2-year
    various regimens        overall survival 74%
Jahnke, Korfel  Retrospective  Retrospective  19  17/19 (13 CR,  6/17  Median progression-free
2006  series with  series with    4 PR)    survival 10 months,
  various  various regimens        median overall
  modalities          survival 22.5 monthsb
aPatients may or may not have received all listed modalities and agents; see referenced articles for details.
bSurvival data also includes patients with secondary intraocular lymphoma.
Abbreviations: PIOL, primary intraocular lymphoma; IV, intravenous; IT, intrathecal; WBRT, whole-brain irradiation; ORT, ocular radiation therapy; MTX, methotrexate; CR, 
complete remission; PO, oral; PR, partial remission; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; CRu, unconﬁ  rmed complete remission.Clinical Ophthalmology 2007:1(3) 254
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vitreous compared with the aqueous in ﬁ  ve of six patients 
in whom both chambers were assayed. Six complete ocular 
responses and one partial response were observed, and two 
patients had persistent PIOL despite detection of micromo-
lar methotrexate concentrations. In the seven patients with 
concurrent PCNSL and PIOL, all had complete responses 
in the brain (Batchelor TT et al 2003). In a study using a 
similar treatment schedule for 25 patients with PCNSL of 
whom ﬁ  ve had ocular involvement, ocular responses were 
observed in four patients, whereas all ﬁ  ve responded in the 
brain, thus underscoring the ability of controlling concurrent 
cerebral disease with systemic chemotherapy (Batchelor T 
et al 2003).
Cytarabine alone at a dose of 2–3 g/m2 achieved an ocular 
response in ﬁ  ve out of six treated patients; however, four 
responses were only partial (Strauchen et al 1989).
A recent study with 10 IOL patients, among them two 
with secondary IOL, prospectively evaluated the efﬁ  cacy and 
aqueous penetration of intravenous ifosfamide, oral trofos-
famide and their active metabolites. Four patients had newly 
diagnosed and six relapsed disease. Ifosfamide doses ranged 
from 1500 to 2000 mg/m2/day (days 1–3), and trofosfamide 
was given at a dose from 150 to 400 mg/day (continuous 
or intermittent administration). All patients responded, and 
progression-free survival (PFS) from ﬁ  rst treatment was 6+ 
to 18 months. Active drug metabolites were detected in the 
aqueous humor in six of six patients treated with ifosfamide, 
and in one out of three patients treated with trofosfamide 
(Jahnke, Wagner et al 2005).
Intrathecal chemotherapy
In two patients with recurrent PIOL, intrathecal administra-
tion of methotrexate and cytarabine resulted in a sustained 
complete remission (Mason et al 2003).
Marked improvement in ocular lymphoma has been 
reported in one patient treated with intrathecal rituximab in 
a phase I study (Rubenstein et al 2004).
High-dose chemotherapy and autologous 
stem cell transplantation
High-dose chemotherapy followed by autologous stem cell 
support has been used for relapsed or refractory PIOL or 
PCNSL. In a study with 22 relapsed or refractory PCNSL/PIOL 
patients, two of the three patients with isolated PIOL achieved 
a sustained complete response, whereas the third patient 
relapsed in the eye after three months and died secondary to 
tumor progression. Five of eight patients with concomitant 
CNS and ocular disease had a partial or complete response. 
Five patients died from treatment complications, including 
two deaths from neurotoxicity (Soussain et al 2001).
In a similar study on intense chemotherapy with stem cell 
rescue with 14 PCNSL patients, two had ocular disease. One 
responded completely, whereas the second patient achieved a 
transient complete response after chemotherapy, but relapsed 
before stem cell rescue (Abrey et al 2003).
Treatment recommendations
Due to the rarity of this condition, literature on the treatment 
of PIOL mainly consists of an abundance of small case series 
which are difﬁ  cult to compare (see above and Tables 2 and 3), 
and the treatment of choice for PIOL therefore remains con-
troversial. Based on the available treatment data, no deﬁ  nite 
treatment recommendations can be given.
In a recent international effort coordinated by the IPCG, 
a retrospective case series of 81 patients with isolated PIOL 
was assembled from 15 centers in seven countries. Twenty-
one patients received local (ocular) treatment alone, ie, 
intraocular methotrexate (n = 6), ocular radiation (n = 14), 
or both modalities (n = 1). Systemic chemotherapy alone 
was administered in 20, and a combination of chemotherapy 
and radiotherapy in 32 patients (ﬁ  ve patients received no 
treatment, and details remained unknown in three). PFS 
and OS were 29.6 months and 57 months, respectively, and 
were unaffected by the choice of therapy. Nineteen patients 
(58%) died of CNS disease. Patients treated with ocular 
therapy alone did not have an increased risk of brain relapse 
(p = 0.6). The authors concluded that the best initial therapy 
in patients with isolated PIOL should be limited to local 
treatments to minimize systemic toxicity (Grimm, Pulido, 
Jahnke et al 2006).
A similar retrospective case series of 225 (164 evaluable) 
PIOL patients with concomitant parenchymal brain involve-
ment was assembled from 15 centers in eight countries by the 
IPCG. Local ocular therapy (mainly radiation) in conjunction 
with treatment for cerebral disease was given to 92 patients, 
and PCNSL therapy without local ocular treatment to 72 
patients. PFS and OS were 18.7 months and 33.1 months, 
respectively. The cause of death in 71% of patients was 
PCNSL progression or relapse. Patients treated with a com-
bination of focal ocular therapy and speciﬁ  c PCNSL therapy 
had signiﬁ  cantly longer PFS (19 months vs 14.2 months, 
p = 0.008). Since patients who received more aggressive 
ocular treatment had an improved PFS, it was concluded 
that the optimal initial therapy in patients with concomitant 
PIOL and PCNSL should include intraocular chemotherapy 
or ocular radiotherapy (Grimm, Pulido, Omuro et al 2006).Clinical Ophthalmology 2007:1(3) 255
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The importance of systemic chemotherapy for cerebral 
disease control in PIOL was emphasized in several studies. 
In one trial with 22 PIOL patients, among them 21 with con-
comitant brain disease, disease control was longer in PIOL 
patients whose treatment included systemic chemotherapy 
as compared to patients treated with radiotherapy alone, 
and ocular disease control was best for patients treated with 
a combination of systemic chemotherapy and ocular radia-
tion (Ferreri et al 2002). A median OS of only 16 months in 
patients treated with chemotherapy not able to penetrate the 
blood-brain barrier has been reported in an Australian study 
(Hoffman et al 2003), this being in contrast to a median OS 
of 39 months in patients with isolated PIOL and 24 months in 
patients with PIOL secondary to CNS disease predominantly 
treated with blood-brain barrier-crossing chemotherapy 
(Hormigo et al 2004). In the latter study, patients whose ocu-
lar disease was identiﬁ  ed and treated before CNS progression 
had a signiﬁ  cantly improved survival, thus underscoring the 
need for CNS disease control and rapid diagnosis of PIOL. 
In a trial with 19 PIOL and three secondary IOL patients, 
median PFS was 12 months for patients treated with systemic 
therapy, but only 5.5 months after local therapy. Cerebral 
relapse occurred in six of nine patients after local therapy, 
but only in one of 13 patients after systemic chemotherapy; a 
second patient developed a systemic relapse (Jahnke, Korfel 
et al 2006).
Conclusions and future directions
Several questions in the diagnosis and management of PIOL 
still remain open, eg, regarding PIOL pathogenesis, prog-
nostic factors, the optimal methotrexate dose in high-dose 
methotrexate-based regimens, and the timing and necessity 
of radiation. Animal models offer the opportunity to study 
various aspects of pathology, pathogenesis and treatment 
in PIOL (Chan et al 2005; Li et al 2006). There is no con-
sensus on the optimal treatment of PIOL, and prognosis 
remains poor despite recent advances in diagnosis and treat-
ment. Recent studies favor the use of systemic high-dose 
methotrexate-based chemotherapy in conjunction with local 
ocular treatment as ﬁ  rst-line management for patients with 
concomitant PIOL and PCNSL. For patients with isolated 
PIOL, the current trend has shifted towards the ﬁ  rst-line use 
of local treatment modalities. Future treatment strategies for 
PIOL/PCNSL could include intravenous rituximab that has 
already proven efﬁ  cient in PCNSL and systemic lymphoma 
(Rubenstein et al 2003; Enting et al 2004; Wong et al 2004; 
Feugier et al 2005). The usefulness of intravitreal rituximab 
administration is under investigation (Kim et al 2006). Based 
on its efﬁ  cacy in systemic lymphomas (Nowakowski et al 
2006), radioimmunotherapy may be an interesting option in 
the future treatment of PIOL/PCNSL. Since dose intensity 
is important for the outcome of PCNSL patients (Kraemer 
et al 2001) and because of favorable neurocognitive out-
comes (McAllister et al 2000), the approach of intraarte-
rial chemotherapy in conjunction with osmotic blood-brain 
barrier disruption deserves further investigation. The role 
of high-dose chemotherapy followed by stem cell support 
should be further investigated in relapsed PIOL/PCNSL, 
and future studies should possibly be extended to ﬁ  rst-line 
treatment of younger patients.
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